Amedeo Smart

Free Medical Literature Service

 

Amedeo

Rheumatoid Arthritis
  Free Subscription

Articles published in
Ann Rheum Dis
    April 2024
  1. IKDAHL E, Semb AG, Kerola AM
    No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register.
    Ann Rheum Dis. 2024 Apr 23:ard-2024-225758. doi: 10.1136/ard-2024-225758.
    >> Share

  2. LUO X, Ren Y, Chen Y
    Gender imbalance in expert panels of recommendations in rheumatology.
    Ann Rheum Dis. 2024;83:682-684.
    >> Share

  3. HERNANDEZ-CRUZ B, Otero-Varela L, Freire-Gonzalez M, Busquets-Perez N, et al
    Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.
    Ann Rheum Dis. 2024 Apr 9:ard-2023-225271. doi: 10.1136/ard-2023-225271.
    >> Share

    March 2024
  4. COHEN P, Ziff D, Lipsky PE
    Morris Ziff.
    Ann Rheum Dis. 2024;83:417-420.
    >> Share

  5. WINTHROP KL, Mease P, Kerschbaumer A, Voll RE, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
    Ann Rheum Dis. 2024;83:409-416.
    >> Share

  6. MELOKHINA V, Paulshus Sundlisaeter N, Sexton J, Sundin U, et al
    Subclinical inflammation and joint damage progression in patients with early RA fulfilling 2011 vs 2022 ACR/EULAR Boolean remission criteria: data from the ARCTIC study.
    Ann Rheum Dis. 2024;83:540-541.
    >> Share

    February 2024
  7. HE Y, Aoun M, Xu Z, Holmdahl R, et al
    Shift in perspective: autoimmunity protecting against rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 27:ard-2023-225237. doi: 10.1136/ard-2023-225237.
    >> Share

  8. VAN DER WOUDE D, Toes REM
    Immune response to post-translationally modified proteins in rheumatoid arthritis: what makes it special?
    Ann Rheum Dis. 2024 Feb 20:ard-2023-224103. doi: 10.1136/ard-2023-224103.
    >> Share


  9. Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study.
    Ann Rheum Dis. 2024;83:e8.
    >> Share


  10. Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis.
    Ann Rheum Dis. 2024;83:e9.
    >> Share

  11. TANG Z, Shi H, Liu HL, Cheng X, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e4.
    >> Share

  12. BARBHAIYA M, Zuily S, Hendry AM, Manneville F, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.
    Ann Rheum Dis. 2024;83:e5.
    >> Share

  13. DAMOISEAUX J, van Beers J
    Correspondence on "ACR/EULAR antiphospholipid syndrome classification criteria".
    Ann Rheum Dis. 2024;83:e6.
    >> Share

  14. ERKAN D, Barbhaiya M, Zuily S, Bertolaccini ML, et al
    Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.
    Ann Rheum Dis. 2024;83:e3.
    >> Share

  15. BARBHAIYA M, Zuily S, Bertolaccini ML, Willis R, et al
    Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
    Ann Rheum Dis. 2024;83:e7.
    >> Share

  16. MIRO-MUR FA, Alijotas-Reig J, Anunciacion-Llunell A, Marques-Soares J, et al
    Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria'.
    Ann Rheum Dis. 2024;83:e2.
    >> Share

  17. PEZOT M, Nocturne G, Belkhir R, Henry J, et al
    Obinutuzumab in patients with Sjogren's disease immunised against rituximab.
    Ann Rheum Dis. 2024;83:407-408.
    >> Share

  18. DORNER T, Kaul M, Szanto A, Tseng JC, et al
    Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjogren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
    Ann Rheum Dis. 2024;83:360-371.
    >> Share

  19. CROWSON CS, Atkinson EJ, Kronzer VL, Kimbrough BA, et al
    Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis.
    Ann Rheum Dis. 2024 Feb 8:ard-2023-225093. doi: 10.1136/ard-2023-225093.
    >> Share

  20. SCHENNING LCM, Ottevanger R, Quint KD, Tas SW, et al
    An ulcerating skin tumour in a patient with rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 5:ard-2023-225436. doi: 10.1136/ard-2023-225436.
    >> Share

  21. HU F, Shi L, Liu X, Chen Y, et al
    Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-alpha in rheumatoid arthritis.
    Ann Rheum Dis. 2024 Feb 1:ard-2023-224878. doi: 10.1136/ard-2023-224878.
    >> Share

    January 2024
  22. WU G, Cao B, Zhai H, Liu B, et al
    EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.
    Ann Rheum Dis. 2024 Jan 25:ard-2023-224852. doi: 10.1136/ard-2023-224852.
    >> Share

  23. HECKERT SL, Maassen JM, le Cessie S, Goekoop-Ruiterman YPM, et al
    Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
    Ann Rheum Dis. 2024;83:161-168.
    >> Share

  24. BONELLI M, Kerschbaumer A, Kastrati K, Ghoreschi K, et al
    Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.
    Ann Rheum Dis. 2024;83:139-160.
    >> Share

  25. TANAKA H, Okada Y, Nakayamada S, Miyazaki Y, et al
    Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.
    Ann Rheum Dis. 2024;83:242-252.
    >> Share

  26. DREHER M, Witte T, Hoeper K, Assmann G, et al
    Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.
    Ann Rheum Dis. 2024;83:184-193.
    >> Share

  27. SCHIFF AE, Wang X, Patel NJ, Kawano Y, et al
    Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
    Ann Rheum Dis. 2024 Jan 10:ard-2023-225162. doi: 10.1136/ard-2023-225162.
    >> Share

  28. AVOUAC J, Hecquet S, Thomas M, Combier A, et al
    Validation of the definition of rheumatoid arthritis flare based on SDAI and CDAI in clinical practice in two French independent cohorts.
    Ann Rheum Dis. 2024 Jan 5:ard-2023-225272. doi: 10.1136/ard-2023-225272.
    >> Share

  29. TEUWEN MMH, van Weely SFE, Vliet Vlieland TPM, van Wissen MAT, et al
    Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-224912. doi: 10.1136/ard-2023-224912.
    >> Share

  30. BAKER JF, ODell JR, England BR, Giles JT, et al
    Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
    Ann Rheum Dis. 2024 Jan 3:ard-2023-225014. doi: 10.1136/ard-2023-225014.
    >> Share


  31. Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2024;83:e1.
    >> Share

  32. CAO S, Li Y, Song R, Meng X, et al
    L-arginine metabolism inhibits arthritis and inflammatory bone loss.
    Ann Rheum Dis. 2024;83:72-87.
    >> Share

  33. BIJLSMA JWJ
    Annals of the Rheumatic Diseases collection on glucocorticoids (2020-2023): novel insights and advances in therapy.
    Ann Rheum Dis. 2024;83:4-8.
    >> Share

  34. BERRY JS, Tarn J, Casement J, Duret PM, et al
    Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.
    Ann Rheum Dis. 2024;83:88-95.
    >> Share

    December 2023
  35. AYMON R, Mongin D, Bergstra SA, Choquette D, et al
    Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
    Ann Rheum Dis. 2023 Dec 8:ard-2023-224670. doi: 10.1136/ard-2023-224670.
    >> Share

  36. TRIAILLE C, Tilman G, Sokolova T, Loriot A, et al
    Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitis.
    Ann Rheum Dis. 2023;82:1538-1546.
    >> Share

  37. YAMADA H, Haraguchi A, Tsuru T, Kondo M, et al
    Low avidity observed for anti-citrullinated peptide antibody is not a general phenomenon for autoantibodies.
    Ann Rheum Dis. 2023;82:1637-1638.
    >> Share

    November 2023
  38. LIEN HJT, Pedersen TT, Jakobsen B, Flatberg A, et al
    Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.
    Ann Rheum Dis. 2023 Nov 30:ard-2023-224644. doi: 10.1136/ard-2023-224644.
    >> Share

  39. PERTSINIDOU E, Saevarsdottir S, Manivel VA, Klareskog L, et al
    In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
    Ann Rheum Dis. 2023 Nov 27:ard-2023-224728. doi: 10.1136/ard-2023-224728.
    >> Share

  40. MOULIN D, Millard M, Taieb M, Michaudel C, et al
    Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Ann Rheum Dis. 2023 Nov 24:ard-2023-224014. doi: 10.1136/ard-2023-224014.
    >> Share

  41. GOLDMANN K, Spiliopoulou A, Iakovliev A, Plant D, et al
    Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.
    Ann Rheum Dis. 2023 Nov 18:ard-2023-224540. doi: 10.1136/ard-2023-224540.
    >> Share

  42. SIMON TA, Dong L, Suissa S, Michaud K, et al
    Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
    Ann Rheum Dis. 2023 Nov 6:ard-2023-224356. doi: 10.1136/ard-2023-224356.
    >> Share


  43. Correction: Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e227.
    >> Share


  44. Correction: Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2023;82:e222.
    >> Share

  45. WOLLHEIM FA
    Nanna Svartz (1890-1986) and the discovery of sulfasalazine.
    Ann Rheum Dis. 2023;82:1382-1386.
    >> Share

  46. SAVIANO A, Manosour AA, Raucci F, Merlino F, et al
    New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function.
    Ann Rheum Dis. 2023;82:1415-1428.
    >> Share

  47. SCHERLINGER M, Schaeverbeke T
    Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'.
    Ann Rheum Dis. 2023;82:e221.
    >> Share

    October 2023
  48. WESTHOVENS R, Verschueren P
    Lessons from negative phase 3 trials in rheumatoid arthritis anno 2023.
    Ann Rheum Dis. 2023 Oct 30:ard-2023-224904. doi: 10.1136/ard-2023-224904.
    >> Share

  49. KONZETT V, Kerschbaumer A, Smolen JS, Kristianslund EK, et al
    Definition of rheumatoid arthritis flare based on SDAI and CDAI.
    Ann Rheum Dis. 2023 Oct 27:ard-2023-224742. doi: 10.1136/ard-2023-224742.
    >> Share

  50. VAN WESEMAEL TJ, Reijm S, Kawakami A, Dorjee AL, et al
    IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Oct 3:ard-2023-224553. doi: 10.1136/ard-2023-224553.
    >> Share


  51. Correction: Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2023;82:e219.
    >> Share

  52. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
    Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
    Ann Rheum Dis. 2023;82:e217.
    >> Share

  53. MA KS, Chiang CH, Chen YW, Wang LT, et al
    Correspondence to 'Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production'.
    Ann Rheum Dis. 2023;82:e216.
    >> Share

    September 2023
  54. KONZETT V, Kerschbaumer A, Smolen JS, Aletaha D, et al
    Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 27:ard-2023-224477. doi: 10.1136/ard-2023-224477.
    >> Share

  55. FLEISCHMANN RM, van der Heijde D, Strand V, Atsumi T, et al
    Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
    Ann Rheum Dis. 2023 Sep 12:ard-2023-224482. doi: 10.1136/ard-2023-224482.
    >> Share

  56. YAP CF, Nair N, de Vries A, Loeff FC, et al
    HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Sep 12:ard-2023-223955. doi: 10.1136/ard-2023-223955.
    >> Share

  57. TAYLOR PC, Weinblatt ME, McInnes IB, Atsumi T, et al
    Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
    Ann Rheum Dis. 2023 Sep 11:ard-2023-224449. doi: 10.1136/ard-2023-224449.
    >> Share


  58. News from EULAR.
    Ann Rheum Dis. 2023;82:1242.
    >> Share

  59. LONGOBARDI S, Lopez-Davis C, Khatri B, Georgescu C, et al
    Autoantibodies identify primary Sjogren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B.
    Ann Rheum Dis. 2023;82:1181-1190.
    >> Share

  60. FERRI C, Giuggioli D, Raimondo V, Fallahi P, et al
    COVID-19 in Italian patients with rheumatic autoimmune systemic diseases.
    Ann Rheum Dis. 2023;82:e211.
    >> Share

    August 2023
  61. VAN OUWERKERK L, Verschueren P, Boers M, Emery P, et al
    Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
    Ann Rheum Dis. 2023 Aug 22:ard-2023-224270. doi: 10.1136/ard-2023-224270.
    >> Share

  62. LILLEGRAVEN S, Paulshus Sundlisaeter N, Aga AB, Sexton J, et al
    Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.
    Ann Rheum Dis. 2023 Aug 22:ard-2023-224476. doi: 10.1136/ard-2023-224476.
    >> Share

  63. ALMAYALI AAH, Boers M, Hartman L, Opris D, et al
    Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.
    Ann Rheum Dis. 2023 Aug 4:ard-2023-223977. doi: 10.1136/ard-2023-223977.
    >> Share

  64. RUSSELL MD, Stovin C, Alveyn E, Adeyemi O, et al
    JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
    Ann Rheum Dis. 2023;82:1059-1067.
    >> Share

  65. BERGSTRA SA, Sepriano A, Chopra A, Winchow LL, et al
    Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registry.
    Ann Rheum Dis. 2023;82:1018-1024.
    >> Share

  66. HUANG YT, Jenkins DA, Peek N, Dixon WG, et al
    High frequency of long-term opioid use among patients with rheumatic and musculoskeletal diseases initiating opioids for the first time.
    Ann Rheum Dis. 2023;82:1116-1117.
    >> Share

  67. LEE S, Choi E, Chae S, Koh JH, et al
    Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling.
    Ann Rheum Dis. 2023;82:1035-1048.
    >> Share

  68. REINISCH W, Hellstrom W, Dolhain RJEM, Sikka S, et al
    Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
    Ann Rheum Dis. 2023;82:1049-1058.
    >> Share

  69. DALBETH N, Neogi T
    Where are the women 'Heroes and Pillars of Rheumatology'?
    Ann Rheum Dis. 2023;82:e199.
    >> Share

    July 2023
  70. SO H, Lam TO, Meng H, Lam SHM, et al
    Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.
    Ann Rheum Dis. 2023 Jul 24:ard-2023-224185. doi: 10.1136/ard-2023-224185.
    >> Share

  71. QIU YY, Neogi T, Muhammad LN, Song J, et al
    Anti-cyclic citrullinated peptide antibody and pain sensitisation in patients with rheumatoid arthritis: a cross-sectional analysis.
    Ann Rheum Dis. 2023 Jul 19:ard-2023-224492. doi: 10.1136/ard-2023-224492.
    >> Share

  72. OZEN G, Pedro S, Michaud K
    Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jul 17:ard-2023-224339. doi: 10.1136/ard-2023-224339.
    >> Share

  73. VAN ESVELD L, Cox JM, Kuijper TM, Bosch TM, et al
    Cost-utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands.
    Ann Rheum Dis. 2023 Jul 9:ard-2023-224190. doi: 10.1136/ard-2023-224190.
    >> Share

  74. OSTERGAARD M, van Vollenhoven RF, Rudin A, Hetland ML, et al
    Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
    Ann Rheum Dis. 2023 Jul 9:ard-2023-224116. doi: 10.1136/ard-2023-224116.
    >> Share

  75. KIMURA A, Takagi T, Thamamongood T, Sakamoto S, et al
    Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.
    Ann Rheum Dis. 2023 Jul 2:ard-2023-224055. doi: 10.1136/ard-2023-224055.
    >> Share

  76. OSKAM N, Ooijevaar-De Heer P, Kos D, Jeremiasse J, et al
    Rheumatoid factor autoantibody repertoire profiling reveals distinct binding epitopes in health and autoimmunity.
    Ann Rheum Dis. 2023;82:945-956.
    >> Share

  77. BASS AR, Abdel-Wahab N, Reid PD, Sparks JA, et al
    Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.
    Ann Rheum Dis. 2023;82:920-926.
    >> Share

  78. KRISTENSEN LE, Danese S, Yndestad A, Wang C, et al
    Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
    Ann Rheum Dis. 2023;82:901-910.
    >> Share

  79. YAZICI H, Yazici Y
    Correspondence on 'classification criteria: time for a rethink 'by D Porter et al'.
    Ann Rheum Dis. 2023;82:e176.
    >> Share

  80. CACCIAPAGLIA F, Manfredi A, Erre G, Piga M, et al
    Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular c
    Ann Rheum Dis. 2023;82:e159.
    >> Share

    June 2023
  81. KUGLER M, Dellinger M, Kartnig F, Muller L, et al
    Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jun 21:ard-2022-223396. doi: 10.1136/ard-2022-223396.
    >> Share

  82. FLEISCHMANN R, Curtis JR, Charles-Schoeman C, Mysler E, et al
    Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Ann Rheum Dis. 2023 Jun 12:ard-2023-223916. doi: 10.1136/ard-2023-223916.
    >> Share


  83. News from EULAR.
    Ann Rheum Dis. 2023;82:886.
    >> Share

  84. DE BENEDETTI F, Grom AA, Brogan PA, Bracaglia C, et al
    Efficacy and safety of emapalumab in macrophage activation syndrome.
    Ann Rheum Dis. 2023;82:857-865.
    >> Share

  85. STYRKARSDOTTIR U, Stefansdottir L, Thorleifsson G, Stefansson OA, et al
    Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect.
    Ann Rheum Dis. 2023;82:873-880.
    >> Share

  86. LI T, Ge C, Kramer A, Sareila O, et al
    Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage.
    Ann Rheum Dis. 2023;82:799-808.
    >> Share

  87. OSPELT C
    Site of invasion revisited: epigenetic drivers of joint destruction in RA.
    Ann Rheum Dis. 2023;82:734-739.
    >> Share

  88. ALETAHA D, Kerschbaumer A, Kastrati K, Dejaco C, et al
    Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
    Ann Rheum Dis. 2023;82:773-787.
    >> Share

  89. FELTEN R, Gottenberg JE
    Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by de Wolff et al.
    Ann Rheum Dis. 2023;82:e149.
    >> Share

  90. DE WOLFF L, Arends S, Verstappen GM, Vissink A, et al
    Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised controlled trial'.
    Ann Rheum Dis. 2023;82:e148.
    >> Share

    May 2023
  91. TAKEUCHI T, Tanaka S, Murata M, Tanaka Y, et al
    Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.
    Ann Rheum Dis. 2023 May 22:ard-2022-223759. doi: 10.1136/ard-2022-223759.
    >> Share

  92. WINTHROP KL, Isaacs JD, Mease PJ, Boumpas DT, et al
    Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
    Ann Rheum Dis. 2023;82:594-598.
    >> Share

  93. BAKER JF, England BR, Mikuls TR
    Response to: 'Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'' by Ruscitti et al.
    Ann Rheum Dis. 2023;82:e120.
    >> Share

  94. RUSCITTI P, Sesti G, Cipriani P, Gerli R, et al
    Correspondence on 'Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e119.
    >> Share

    April 2023
  95. BOERS M
    Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
    Ann Rheum Dis. 2023 Apr 20:ard-2022-223599. doi: 10.1136/ard-2022-223599.
    >> Share

  96. STUDENIC P, Aletaha D, Stamm TA, de Wit M, et al
    Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic et al.
    Ann Rheum Dis. 2023 Apr 20:ard-2022-223627. doi: 10.1136/ard-2022-223627.
    >> Share

  97. MEYER A, Sienes RE, Nijim W, Zanotti B, et al
    Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
    Ann Rheum Dis. 2023;82:483-495.
    >> Share

  98. REUTER K, Rocca E
    Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e91.
    >> Share

  99. ZHENG BK
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2023;82:e93.
    >> Share

  100. GEORGIADIS AN, Pelechas E, Voulgari PV, Drosos AA, et al
    Correspondence on 'Cardiovascular effects of biological versus csDMARD therapy in treatment naive, early rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e89.
    >> Share

  101. PLEIN S, Buch MH
    Response to: 'Correspondence on 'Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis'' by Georgiadis et al.
    Ann Rheum Dis. 2023;82:e90.
    >> Share

  102. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
    Ann Rheum Dis. 2023;82:e94.
    >> Share

  103. ZERVOU MI, Goulielmos GN
    Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
    Ann Rheum Dis. 2023;82:e87.
    >> Share

  104. CONRAD N, McInnes IB, Mcmurray JJV, Sattar N, et al
    Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management?
    Ann Rheum Dis. 2023;82:457-459.
    >> Share

  105. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
    Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al.
    Ann Rheum Dis. 2023;82:e92.
    >> Share

  106. MOLANDER V, Askling J
    Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
    Ann Rheum Dis. 2023;82:e88.
    >> Share

    March 2023
  107. YAMADA S, Nagafuchi Y, Wang M, Ota M, et al
    Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance.
    Ann Rheum Dis. 2023 Mar 14:ard-2022-223645. doi: 10.1136/ard-2022-223645.
    >> Share

  108. HUSS V, Bower H, Hellgren K, Frisell T, et al
    Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
    Ann Rheum Dis. 2023 Mar 3:ard-2022-223636. doi: 10.1136/ard-2022-223636.
    >> Share


  109. Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Ann Rheum Dis. 2023;82:e76.
    >> Share


  110. News from EULAR.
    Ann Rheum Dis. 2023;82:448.
    >> Share

  111. LOPES AP, Hillen MR, Hinrichs AC, Blokland SL, et al
    Deciphering the role of cDC2s in Sjogren's syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity.
    Ann Rheum Dis. 2023;82:374-383.
    >> Share

  112. WANG B, Chen S, Xuan J, Li Y, et al
    Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'.
    Ann Rheum Dis. 2023;82:e67.
    >> Share

  113. FELTEN R, Gottenberg JE
    Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al.
    Ann Rheum Dis. 2023;82:e68.
    >> Share

  114. AYDIN SZ, Hepworth E, Tugwell P
    Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Ann Rheum Dis. 2023;82:e69.
    >> Share

  115. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al.
    Ann Rheum Dis. 2023;82:e70.
    >> Share

  116. MOUTSOPOULOS HM
    Correspondence on 'Jan Gosta Waldenstrom and rheumatology'.
    Ann Rheum Dis. 2023;82:e59.
    >> Share

  117. NOVELLA-NAVARRO M, Plasencia-Rodriguez C, Tornero C, Navarro-Compan V, et al
    Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e55.
    >> Share

  118. ROODENRIJS NMT, Welsing PMJ, van der Goes MC, Jacobs JW, et al
    Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al.
    Ann Rheum Dis. 2023;82:e56.
    >> Share

    February 2023
  119. SMITH SL, Alexander S, Nair N, Viatte S, et al
    Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
    Ann Rheum Dis. 2023 Feb 21:annrheumdis-2022-222519. doi: 10.1136/ard-2022-222519
    >> Share

  120. FRISELL T, Bower H, Morin M, Baecklund E, et al
    Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
    Ann Rheum Dis. 2023 Feb 14:ard-2022-223762. doi: 10.1136/ard-2022-223762.
    >> Share

  121. O'NEIL LJ, Oliveira CB, Wang X, Navarrete M, et al
    Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Feb 3:ard-2022-223568. doi: 10.1136/ard-2022-223568.
    >> Share


  122. Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e53.
    >> Share

  123. TARANNUM S, Widdifield J, Wu CF, Johnson SR, et al
    Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study.
    Ann Rheum Dis. 2023;82:283-291.
    >> Share

  124. POMBO-SUAREZ M, Sanchez-Piedra C, Gomez-Reino J, Lauper K, et al
    After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
    Ann Rheum Dis. 2023;82:175-181.
    >> Share

  125. HOSONO Y, Sie B, Pinal-Fernandez I, Pak K, et al
    Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies.
    Ann Rheum Dis. 2023;82:246-252.
    >> Share

  126. SUN T, Ni J
    Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e50.
    >> Share

  127. GILBERT BTP, Finckh A, Alpizar Rodriguez D
    Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'' by Sun and Ni.
    Ann Rheum Dis. 2023;82:e51.
    >> Share

  128. DE COCK D, Soenen I, Bertrand D, Pazmino S, et al
    Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'.
    Ann Rheum Dis. 2023;82:e44.
    >> Share

  129. RUYSSEN-WITRAND A, Soubrier M, Basch A, Truchetet ME, et al
    Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'.
    Ann Rheum Dis. 2023;82:e32.
    >> Share

  130. CIUREA A, Finckh A
    Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al.
    Ann Rheum Dis. 2023;82:e33.
    >> Share

    January 2023
  131. DOUGADOS M, Charles-Schoeman C, Szekanecz Z, Giles JT, et al
    Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
    Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406.
    >> Share

  132. NII T, Maeda Y, Motooka D, Naito M, et al
    Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:annrheumdis-2022-222881. doi: 10.1136/ard-2022-222881
    >> Share

  133. KERSCHBAUMER A, Stimakovits NM, Smolen JS, Stefanova T, et al
    Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:ard-2022-223349. doi: 10.1136/ard-2022-223349.
    >> Share

  134. POPE JE, Fleischmann RM
    Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
    Ann Rheum Dis. 2023 Jan 6:ard-2022-223071. doi: 10.1136/ard-2022-223071.
    >> Share

  135. GWINNUTT JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, et al
    2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
    Ann Rheum Dis. 2023;82:48-56.
    >> Share

  136. VAN MULLIGEN E, de Jong PHP
    Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis' by Garcia et al.
    Ann Rheum Dis. 2023;82:e10.
    >> Share

  137. GARCIA IE, Abud-Mendoza C
    Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e9.
    >> Share

  138. JONG GP, Pan LF, Lin TK, Chen HY, et al
    Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease'.
    Ann Rheum Dis. 2023;82:e11.
    >> Share

  139. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
    Response to 'Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al.
    Ann Rheum Dis. 2023;82:e12.
    >> Share

  140. SCHULZE-KOOPS H, Skapenko A, Krause A, Krueger K, et al
    Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Ann Rheum Dis. 2023;82:e1.
    >> Share

  141. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al.
    Ann Rheum Dis. 2023;82:e2.
    >> Share

    December 2022
  142. HEBING RC, Lin M, Bulatovic Calasan M, Muller IB, et al
    Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.
    Ann Rheum Dis. 2022 Dec 21:ard-2022-223398. doi: 10.1136/ard-2022-223398.
    >> Share

  143. VAN OUWERKERK L, Boers M, Emery P, de Jong PH, et al
    Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 16:ard-2022-223443. doi: 10.1136/ard-2022-223443.
    >> Share

  144. KRONZER VL, Sparks JA
    Occupational inhalants, genetics and the respiratory mucosal paradigm for ACPA-positive rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223286. doi: 10.1136/ard-2022-223286.
    >> Share

  145. TANG B, Liu Q, Ilar A, Wiebert P, et al
    Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223134. doi: 10.1136/ard-2022-223134.
    >> Share

  146. CURTIS JR, Yamaoka K, Chen YH, Bhatt DL, et al
    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Dec 5:annrheumdis-2022-222543. doi: 10.1136/ard-2022-222543.
    >> Share

  147. CALISKAN Y
    News from EULAR.
    Ann Rheum Dis. 2022;81:1767.
    >> Share

  148. KAWANO Y, Patel NJ, Wang X, Cook CE, et al
    Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
    Ann Rheum Dis. 2022;81:1742-1749.
    >> Share

  149. PRINGLE S, Verstappen GM, Bootsma H, Kroese FGM, et al
    Role of interaction between B cells and epithelial cells in pSS.
    Ann Rheum Dis. 2022;81:e260.
    >> Share

  150. RIVIERE E, Mariette X, Nocturne G
    Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle et al.
    Ann Rheum Dis. 2022;81:e261.
    >> Share

  151. WU BY, Chan CH, Wei JC
    Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'.
    Ann Rheum Dis. 2022;81:e243.
    >> Share

  152. HE P, Zhu H, Wu LF, Deng FY, et al
    Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu.
    Ann Rheum Dis. 2022;81:e259.
    >> Share

  153. WANG H, Niu L
    Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'.
    Ann Rheum Dis. 2022;81:e258.
    >> Share

    November 2022
  154. SOLOMON DH, Giles JT, Liao KP, Ridker PM, et al
    Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 30:ard-2022-223302. doi: 10.1136/ard-2022-223302.
    >> Share

  155. BERGSTRA SA, Sepriano A, Kerschbaumer A, van der Heijde D, et al
    Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 21:ard-2022-223358. doi: 10.1136/ard-2022-223358.
    >> Share

  156. SEPRIANO A, Kerschbaumer A, Bergstra SA, Smolen JS, et al
    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 14. pii: ard-2022-223357. doi: 10.1136/ard-2022-223357.
    >> Share

  157. KERSCHBAUMER A, Sepriano A, Bergstra SA, Smolen JS, et al
    Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 11. pii: ard-2022-223365. doi: 10.1136/ard-2022-223365.
    >> Share

  158. SMOLEN JS, Landewe RBM, Bergstra SA, Kerschbaumer A, et al
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Ann Rheum Dis. 2022 Nov 10. pii: ard-2022-223356. doi: 10.1136/ard-2022-223356.
    >> Share

  159. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
    Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US
    Ann Rheum Dis. 2022;81:e225.
    >> Share

  160. ZHENG W, Leong PY, Wei JC
    Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry stu
    Ann Rheum Dis. 2022;81:e224.
    >> Share

  161. KEDOR C, Zernicke J, Feist E
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e234.
    >> Share

  162. RUSCITTI P, Stamm TA, Giacomelli R
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e233.
    >> Share

  163. MURAVIOV Y, Muraviova L
    Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'.
    Ann Rheum Dis. 2022;81:e232.
    >> Share

  164. RUSCITTI P, Bruno F, Berardicurti O, Acanfora C, et al
    Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti et al' by Ch
    Ann Rheum Dis. 2022;81:e221.
    >> Share

    October 2022
  165. STUDENIC P, Aletaha D, de Wit M, Stamm TA, et al
    American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
    Ann Rheum Dis. 2022 Oct 24. pii: ard-2022-223413. doi: 10.1136/ard-2022-223413.
    >> Share

  166. ZHENG Z, Chang L, Mu J, Ni Q, et al
    Database of synovial T cell repertoire of rheumatoid arthritis patients identifies cross-reactive potential against pathogens including unencountered SARS-CoV-2.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222763. doi: 10.1136/ard-2022-222763.
    >> Share

  167. GESSL I, Hana CA, Deimel T, Durechova M, et al
    Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222787. doi: 10.1136/ard-2022-222787.
    >> Share

  168. TU J, Chen W, Fang Y, Han D, et al
    PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222708. doi: 10.1136/ard-2022-222708.
    >> Share

  169. HOISNARD L, Pina Vegas L, Dray-Spira R, Weill A, et al
    Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222824. doi: 10.1136/ard-2022-222824.
    >> Share

  170. DOUMEN M, Pazmino S, Bertrand D, De Cock D, et al
    Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response.
    Ann Rheum Dis. 2022;81:1385-1391.
    >> Share

  171. YANG Y, He X, Yao M, Xing W, et al
    Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'' by Ma et al.
    Ann Rheum Dis. 2022;81:e207.
    >> Share

  172. MA KS, Wang LT, Tsai SY
    Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.
    Ann Rheum Dis. 2022;81:e206.
    >> Share

  173. VAN MULLIGEN E, de Jong PHP
    Response to: 'Tapering antirheumatic drugs in a resource-poor setting: real-world evidence' by Haroon et al.
    Ann Rheum Dis. 2022;81:e209.
    >> Share

  174. HAROON M, Khan Z, Aamer M
    Tapering antirheumatic drugs in a resource-poor setting: real-world evidence.
    Ann Rheum Dis. 2022;81:e208.
    >> Share

  175. ANSARIN K, Taghizadieh A, Safiri S, Malek Mahdavi A, et al
    COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs.
    Ann Rheum Dis. 2022;81:e190.
    >> Share

    September 2022
  176. MOLANDER V, Bower H, Frisell T, Delcoigne B, et al
    Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Sep 23. pii: ard-2022-223050. doi: 10.1136/ard-2022-223050.
    >> Share

  177. CHARLES-SCHOEMAN C, Buch MH, Dougados M, Bhatt DL, et al
    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
    Ann Rheum Dis. 2022 Sep 22. pii: ard-2022-222259. doi: 10.1136/ard-2022-222259.
    >> Share

  178. FEIST E, Fatenejad S, Grishin S, Korneva E, et al
    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled
    Ann Rheum Dis. 2022 Sep 15. pii: ard-2022-222630. doi: 10.1136/ard-2022-222630.
    >> Share

    August 2022
  179. CHENG M, Zhao Y, Cui Y, Zhong C, et al
    Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis.
    Ann Rheum Dis. 2022 Aug 19. pii: ard-2022-222871. doi: 10.1136/ard-2022-222871.
    >> Share

  180. BALANESCU AR, Citera G, Pascual-Ramos V, Bhatt DL, et al
    Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Aug 3. pii: ard-2022-222405. doi: 10.1136/ard-2022-222405.
    >> Share

  181. HUGLE T
    Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology.
    Ann Rheum Dis. 2022;81:1072-1075.
    >> Share

  182. CARDENAS-DE LA GARZA JA, Arvizu-Rivera RI, Galarza-Delgado DA
    Should patients starting biologics be screened for COVID-19?
    Ann Rheum Dis. 2022;81:e150.
    >> Share

    July 2022
  183. SMEELE HTW, Roder E, Mulders AGMGJ, Steegers EAP, et al
    Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring.
    Ann Rheum Dis. 2022 Jul 11. pii: ard-2022-222679. doi: 10.1136/ard-2022-222679.
    >> Share

  184. SEROR R, Baron G, Camus M, Cornec D, et al
    Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:979-989.
    >> Share

  185. BAI W, Liu H, Dou L, Yang Y, et al
    Pilot study of baricitinib for active Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:1050-1052.
    >> Share

  186. VAN DER MEULEN TA, Vissink A, Bootsma H, Spijkervet FKL, et al
    Microbiome in Sjogren's syndrome: here we are.
    Ann Rheum Dis. 2022;81:e114.
    >> Share

  187. MANASSON J, Blank RB, Scher JU
    Response to: 'Microbiome in Sjogren's syndrome: here we are' by van der Meulen et al.
    Ann Rheum Dis. 2022;81:e115.
    >> Share

    June 2022
  188. QIN Y, Cai ML, Jin HZ, Huang W, et al
    Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-alpha-mediated ERK1/2 and JAK-STAT1 pathways.
    Ann Rheum Dis. 2022 Jun 27. pii: ard-2022-222605. doi: 10.1136/ard-2022-222605.
    >> Share

  189. KERSCHBAUMER A, Rivai ZI, Smolen JS, Aletaha D, et al
    Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Jun 20. pii: annrheumdis-2021-221807.
    >> Share

  190. NEMETH T, Nagy G, Pap T
    Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
    Ann Rheum Dis. 2022 Jun 17. pii: annrheumdis-2021-222021.
    >> Share

  191. LAUPER K, Ludici M, Mongin D, Bergstra SA, et al
    Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2022 Jun 15. pii: annrheumdis-2022-222586.
    >> Share

  192. VISMAN IM, Boers M, Vedder D, Twisk JW, et al
    Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years.
    Ann Rheum Dis. 2022 Jun 14. pii: annrheumdis-2022-222207.
    >> Share

  193. COOLES FAH, Tarn J, Lendrem DW, Naamane N, et al
    Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
    Ann Rheum Dis. 2022 Jun 9. pii: annrheumdis-2022-222370.
    >> Share

  194. KVIEN TK
    EULAR 75-year anniversary: commentaries on key ARD papers from 1947.
    Ann Rheum Dis. 2022;81:751-752.
    >> Share

  195. DELCOIGNE B, Ljung L, Provan SA, Glintborg B, et al
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
    Ann Rheum Dis. 2022;81:789-797.
    >> Share

  196. DROSOS GC, Vedder D, Houben E, Boekel L, et al
    EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Ann Rheum Dis. 2022;81:768-779.
    >> Share

  197. RUSCITTI P, Stamm TA, Giacomelli R
    Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease.
    Ann Rheum Dis. 2022;81:e103.
    >> Share

  198. KEDOR C, Listing J, Zernicke J, Feist E, et al
    Response to: 'Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti et al.
    Ann Rheum Dis. 2022;81:e104.
    >> Share

  199. MINOIA F, Ravelli A
    Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang et al.
    Ann Rheum Dis. 2022;81:e100.
    >> Share

  200. ZHANG L, Yang X, Li TF, Liu X, et al
    Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.
    Ann Rheum Dis. 2022;81:e99.
    >> Share

    May 2022
  201. BOERS M, Hartman L, Opris-Belinski D, Bos R, et al
    Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2021-221957.
    >> Share

  202. DAIEN C, Krogulec M, Gineste P, Steens JM, et al
    Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2022-222228.
    >> Share

  203. BUGATTI S, De Stefano L, D'Onofrio B, Nicrosini A, et al
    Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 May 27. pii: annrheumdis-2022-222436.
    >> Share

  204. ROUDIER J
    Correspondence on "Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis" by Maggi et al.
    Ann Rheum Dis. 2022 May 20. pii: annrheumdis-2022-222750.
    >> Share

  205. ROSENBAUM JT, Gill T, Martin TM, Friedman M, et al
    Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?
    Ann Rheum Dis. 2022;81:618-621.
    >> Share

  206. BROEREN MGA, Wang JJ, Balzaretti G, Groenen PJTA, et al
    Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:644-652.
    >> Share

  207. BUCH MH, Maksymowych WP, Boers M
    Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies.
    Ann Rheum Dis. 2022;81:741-742.
    >> Share

    April 2022
  208. DE STEFANO L, D'Onofrio B, Sakellariou G, Manzo A, et al
    Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic.
    Ann Rheum Dis. 2022 Apr 29. pii: annrheumdis-2022-222264.
    >> Share

  209. VAN OUWERKERK L, Palmowski A, Nevins IS, Buttgereit F, et al
    Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2022-222338.
    >> Share

  210. SAEVARSDOTTIR S, Stefansdottir L, Sulem P, Thorleifsson G, et al
    Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
    Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2021-221754.
    >> Share

  211. REIJM S, Brehler AS, Rantapaa-Dahlqvist S, Kawakami A, et al
    Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2022-222326.
    >> Share

  212. MAGGI J, Carrascal M, Soto L, Neira O, et al
    Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.
    Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2021-220371.
    >> Share

  213. VAN LINT JA, van Hunsel FPAM, Tas SW, Vonkeman HE, et al
    Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
    Ann Rheum Dis. 2022;81:597-599.
    >> Share

  214. SAPER VE, Chen G, Guillerman RP, Khatri P, et al
    Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al.
    Ann Rheum Dis. 2022;81:e62.
    >> Share

  215. STUDENIC P, Felson DT, de Wit M, Smolen JS, et al
    Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti et al.
    Ann Rheum Dis. 2022;81:e56.
    >> Share

    March 2022
  216. VERSTAPPEN M, Huizinga TW, van der Helm-van Mil AH
    No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years.
    Ann Rheum Dis. 2022 Mar 2. pii: annrheumdis-2022-222145.
    >> Share

  217. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
    Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
    Ann Rheum Dis. 2022;81:433-439.
    >> Share

  218. LIU D, Zhang F, Cao H, Wang X, et al
    Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?
    Ann Rheum Dis. 2022;81:e36.
    >> Share

  219. YAMAMOTO M, Yoshikawa N, Tanaka H
    Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis.
    Ann Rheum Dis. 2022;81:e50.
    >> Share

  220. REGUEIRO C, Gonzalez A
    Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al.
    Ann Rheum Dis. 2022;81:e38.
    >> Share

  221. MARTINSSON K, Durholz K, Schett G, Zaiss MM, et al
    Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA.
    Ann Rheum Dis. 2022;81:445-447.
    >> Share

  222. SAPER VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, et al
    Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
    Ann Rheum Dis. 2022;81:406-415.
    >> Share

  223. GHALANDARI N, Kemper E, Crijns IH, Wolbink G, et al
    Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
    Ann Rheum Dis. 2022;81:402-405.
    >> Share

    February 2022
  224. ARAUJO CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, et al
    Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
    Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221916.
    >> Share

  225. LOPEZ-ROMERO P, de la Torre I, Haladyj E, Aletaha D, et al
    Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221323.
    >> Share

  226. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
    Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson et al.
    Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221941.
    >> Share

  227. FERREIRA RJO, Welsing PMJ, Jacobs JW, Gossec L, et al
    Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al.
    Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221917.
    >> Share

  228. JIN S, Jiang N, Huo Y, Duan X, et al
    Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations.
    Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2021-221841.
    >> Share

  229. TEDESCHI SK, Stratton J, Ellrodt JE, Whelan MG, et al
    Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.
    Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2022-222232.
    >> Share

  230. MEDEIROS-RIBEIRO AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, et al
    Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
    Ann Rheum Dis. 2022 Feb 8. pii: annrheumdis-2021-221735.
    >> Share

  231. SYMONS RA, Colella F, Collins FL, Rafipay AJ, et al
    Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis.
    Ann Rheum Dis. 2022;81:214-224.
    >> Share

  232. VAN DER HELM-VAN MIL A, Landewe RB
    Response to: 'The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis' by Rothschild.
    Ann Rheum Dis. 2022;81:e19.
    >> Share

  233. ROTHSCHILD BM
    The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis.
    Ann Rheum Dis. 2022;81:e18.
    >> Share

    January 2022
  234. KHOSROW-KHAVAR F, Kim SC, Lee H, Lee SB, et al
    Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
    Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-221915.
    >> Share

  235. GE C, Weisse S, Xu B, Dobritzsch D, et al
    Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor.
    Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-220500.
    >> Share


  236. Correction: Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis.
    Ann Rheum Dis. 2022;81:e17.
    >> Share

  237. LEE YH
    Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study.
    Ann Rheum Dis. 2022;81:e3.
    >> Share

  238. INAMO J
    Response to: 'Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Lee.
    Ann Rheum Dis. 2022;81:e4.
    >> Share

  239. KISSEL T, van Wesemael TJ, Lundquist A, Kokkonen H, et al
    Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.
    Ann Rheum Dis. 2022;81:141-143.
    >> Share

    December 2021
  240. BUGATTI S, De Stefano L, Balduzzi S, Greco MI, et al
    Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1635-1638.
    >> Share

  241. ROSENZWAJG M, Lorenzon R, Klatzmann D
    Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al.
    Ann Rheum Dis. 2021;80:e197.
    >> Share

  242. MEYER A, Wittekind PS, Kotschenreuther K, Schiller J, et al
    Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
    Ann Rheum Dis. 2021;80:e196.
    >> Share

  243. PEREZ-GARCIA LF, Roder E, Goekoop RJ, Hazes JMW, et al
    Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility).
    Ann Rheum Dis. 2021;80:1545-1552.
    >> Share

  244. GRAALMANN T, Borst K, Manchanda H, Vaas L, et al
    B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner.
    Ann Rheum Dis. 2021;80:1537-1544.
    >> Share

    November 2021
  245. SIMADER E, Tobudic S, Mandl P, Haslacher H, et al
    Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
    Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221347.
    >> Share

  246. BALSA A, Garcia de Yebenes MJ, Carmona L
    Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.
    Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221163.
    >> Share

  247. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
    Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.
    Ann Rheum Dis. 2021 Nov 16. pii: annrheumdis-2021-221653.
    >> Share

  248. SIDDLE HJ, Chapman LS, Mankia K, Zabalan C, et al
    Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.
    Ann Rheum Dis. 2021 Nov 8. pii: annrheumdis-2021-221160.
    >> Share

  249. WINTHROP KL, Tanaka Y, Takeuchi T, Kivitz A, et al
    Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
    Ann Rheum Dis. 2021 Nov 5. pii: annrheumdis-2021-221051.
    >> Share

  250. TANAKA Y, Oba K, Takeuchi T
    Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
    Ann Rheum Dis. 2021;80:e173.
    >> Share

  251. BERKHOUT LC, l'Ami MJ, Wolbink GJ, Rispens T, et al
    Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
    Ann Rheum Dis. 2021;80:e172.
    >> Share

  252. CHEN MH, Lee IC, Chen MH, Hou MC, et al
    Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
    Ann Rheum Dis. 2021;80:1393-1399.
    >> Share

  253. NABI H, Georgiadis S, Loft AG, Hendricks O, et al
    Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Ann Rheum Dis. 2021;80:1400-1409.
    >> Share

    October 2021
  254. TAYLOR PC, Takeuchi T, Burmester GR, Durez P, et al
    Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Ann Rheum Dis. 2021 Oct 27. pii: annrheumdis-2021-221276.
    >> Share

  255. LI X, Tong X, Yeung WWY, Kuan P, et al
    Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
    Ann Rheum Dis. 2021 Oct 22. pii: annrheumdis-2021-221571.
    >> Share

  256. CHRISTENSEN IE, Lillegraven S, Mielnik P, Bakland G, et al
    Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-221007.
    >> Share

  257. IBANEZ-COSTA A, Perez-Sanchez C, Patino-Trives AM, Luque-Tevar M, et al
    Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-220308.
    >> Share

  258. WINTHROP KL, Nash P, Yamaoka K, Mysler E, et al
    Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
    Ann Rheum Dis. 2021 Oct 6. pii: annrheumdis-2021-220822.
    >> Share

  259. CAPELUSNIK D, Aletaha D
    Baseline predictors of different types of treatment success in rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 4. pii: annrheumdis-2021-220853.
    >> Share

  260. FLOUDAS A, Neto N, Orr C, Canavan M, et al
    Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 1. pii: annrheumdis-2021-220458.
    >> Share

  261. MEEHAN GR, Thomas R, Al Khabouri S, Wehr P, et al
    Preclinical models of arthritis for studying immunotherapy and immune tolerance.
    Ann Rheum Dis. 2021;80:1268-1277.
    >> Share

  262. NIKIPHOROU E, Santos EJF, Marques A, Bohm P, et al
    2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1278-1285.
    >> Share

    September 2021
  263. YOSHII I, Sawada N, Chijiwa T, Kokei S, et al
    Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Sep 11. pii: annrheumdis-2021-221093.
    >> Share

  264. MINOIA F, Ravelli A
    Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.
    Ann Rheum Dis. 2021;80:e146.
    >> Share

  265. WANG R, Li T, Ye S, Tan W, et al
    Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.
    Ann Rheum Dis. 2021;80:e145.
    >> Share

  266. OZEN G, Michaud K
    Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al.
    Ann Rheum Dis. 2021;80:e141.
    >> Share

  267. JONSSON R
    Henrik Sjogren (1899-1986): the syndrome and his legacy.
    Ann Rheum Dis. 2021;80:1108-1109.
    >> Share

  268. MAASSEN JM, Dos Santos Sobrin R, Bergstra SA, Goekoop R, et al
    Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
    Ann Rheum Dis. 2021;80:1124-1129.
    >> Share

  269. LIOU YS, Lin TK, Chen HY, Jong GP, et al
    Medications associated with fracture risk in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021;80:e140.
    >> Share

    August 2021
  270. HECKERT SL, Bergstra SA, Matthijssen XME, Goekoop-Ruiterman YPM, et al
    Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220882.
    >> Share

  271. WANG Y, Xie X, Zhang C, Su M, et al
    Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220066.
    >> Share

  272. WALLACE ZS, Sparks JA, Robinson PC, Machado PM, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220960.
    >> Share

  273. GREMESE E, Ferraccioli G
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220932.
    >> Share

  274. NAGY G, Roodenrijs NMT, Welsing PMJ, Kedves M, et al
    EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 18. pii: annrheumdis-2021-220973.
    >> Share

  275. VAN VOLLENHOVEN RF, Tas SW, Nurmohamed MT
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221146.
    >> Share

  276. HOLTEN K, Paulshus Sundlisater N, Lillegraven S, Sexton J, et al
    Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-220750.
    >> Share

  277. SPARKS JA, Wallace ZS, Seet AM, Robinson PC, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221157.
    >> Share

  278. PLATZER A, Alasti F, Smolen JS, Aletaha D, et al
    Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.
    Ann Rheum Dis. 2021 Aug 10. pii: annrheumdis-2021-220331.
    >> Share

  279. MANKIA K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, et al
    EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 6. pii: annrheumdis-2021-220884.
    >> Share

  280. NASONOV E, Fatenejad S, Feist E, Ivanova M, et al
    Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-219876.
    >> Share

  281. SPARKS JA
    Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220856.
    >> Share

  282. PALOMAKI A, Palotie A, Koskela J, Eklund KK, et al
    Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220698.
    >> Share

  283. VALLEJO-YAGUE E, Keystone EC, Kandhasamy S, Micheroli R, et al
    Primary and secondary non-response: in need of operational definitions in observational studies.
    Ann Rheum Dis. 2021;80:961-964.
    >> Share

  284. NAKAMURA H, Tanaka T, Pranzatelli T, Ji Y, et al
    Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjogren's syndrome-like phenotype in mice.
    Ann Rheum Dis. 2021;80:1031-1039.
    >> Share

  285. WANG H, Stewart S, Darlow B, Horgan B, et al
    Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016-2020.
    Ann Rheum Dis. 2021;80:1095-1096.
    >> Share

  286. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
    Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
    Ann Rheum Dis. 2021;80:1086-1093.
    >> Share

  287. MATTHIJSSEN XME, Wouters F, Sidhu N, Niemantsverdriet E, et al
    Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.
    Ann Rheum Dis. 2021;80:974-980.
    >> Share

  288. ASSAN F, Seror R, Mariette X, Nocturne G, et al
    New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS.
    Ann Rheum Dis. 2021;80:e122.
    >> Share

    July 2021
  289. REDEKER I, Albrecht K, Kekow J, Burmester GR, et al
    Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
    Ann Rheum Dis. 2021 Jul 28. pii: annrheumdis-2021-220651.
    >> Share

  290. WOUTERS F, Maurits MP, van Boheemen L, Verstappen M, et al
    Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 20. pii: annrheumdis-2021-220546.
    >> Share


  291. Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 6. pii: annrheumdis-2017-211351.
    >> Share

  292. DUMOULIN QA, Matthijssen XME, Wouters F, Krijbolder DI, et al
    Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220511.
    >> Share

  293. GESSL I, Aletaha D, Mandl P
    Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220922.
    >> Share

  294. OCON AJ, Reed G, Pappas DA, Curtis JR, et al
    Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 2. pii: annrheumdis-2021-220577.
    >> Share

  295. WONG AY, MacKenna B, Morton CE, Schultze A, et al
    Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
    Ann Rheum Dis. 2021;80:943-951.
    >> Share

  296. JOUSSE-JOULIN S, D'Agostino MA, Hocevar A, Naredo E, et al
    Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's sy
    Ann Rheum Dis. 2021;80:e112.
    >> Share

  297. LAI SW, Kuo YH, Liao KF
    Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease.
    Ann Rheum Dis. 2021;80:e105.
    >> Share

  298. COIFFIER G, Martel A, Albert JD, Lescoat A, et al
    Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
    Ann Rheum Dis. 2021;80:e111.
    >> Share

  299. TRAVES PG, Murray B, Campigotto F, Galien R, et al
    JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Ann Rheum Dis. 2021;80:865-875.
    >> Share

    June 2021
  300. JAIN S, Dhir V
    Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220816.
    >> Share

  301. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir et al.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220857.
    >> Share

  302. ALBACH FN, Burmester GR, Biesen R
    Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Ann Rheum Dis. 2021 Jun 24. pii: annrheumdis-2021-220834.
    >> Share

  303. SHIPA MRA, Amarnani R, Yeoh SA, Mainuddin MD, et al
    Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy.
    Ann Rheum Dis. 2021 Jun 23. pii: annrheumdis-2021-220642.
    >> Share

  304. JAIN S, Dhir V, Aggarwal A, Gupta R, et al
    Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.
    Ann Rheum Dis. 2021 Jun 10. pii: annrheumdis-2021-220512.
    >> Share

  305. PAULSHUS SUNDLISATER N, Aga AB, Olsen IC, Hammer HB, et al
    Joint tenderness and ultrasound inflammation in DMARD-naive patients with early rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jun 3. pii: annrheumdis-2021-220265.
    >> Share

  306. CROW MK
    Charles L Christian: model physician scientist and mentor.
    Ann Rheum Dis. 2021;80:685-688.
    >> Share

  307. ANSALONE C, Cole J, Chilaka S, Sunzini F, et al
    TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors.
    Ann Rheum Dis. 2021;80:748-757.
    >> Share

  308. HAYER S, Vervoordeldonk MJ, Denis MC, Armaka M, et al
    'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.
    Ann Rheum Dis. 2021;80:714-726.
    >> Share

    May 2021
  309. SPARKS JA, Wallace ZS, Seet AM, Gianfrancesco MA, et al
    Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220418.
    >> Share

  310. JOHNSON TM, Sayles HR, Baker JF, George MD, et al
    Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220125.
    >> Share

  311. D'ONOFRIO B, De Stefano L, Palermo BL, Xoxi B, et al
    Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220219.
    >> Share

  312. LIN TK, Pan LF, Jong GP
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220453.
    >> Share

  313. GONG Z, Zhang F
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220494.
    >> Share

  314. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220477.
    >> Share

  315. TAKANASHI S, Kaneko Y, Takeuchi T
    Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 7. pii: annrheumdis-2021-220315.
    >> Share


  316. Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Ann Rheum Dis. 2021;80:e83.
    >> Share

  317. ROGIER C, van Dijk BT, Brouwer E, de Jong PHP, et al
    Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints.
    Ann Rheum Dis. 2021;80:668-669.
    >> Share

  318. SCHULZE-KOOPS H, Krueger K, Vallbracht I, Hasseli R, et al
    Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
    Ann Rheum Dis. 2021;80:e67.
    >> Share

  319. ROMAO VC, Cruz-Machado AR, Fonseca JE
    Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al.
    Ann Rheum Dis. 2021;80:e76.
    >> Share

  320. ZHAO J, Pang R, Wu J, Guo Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.
    Ann Rheum Dis. 2021;80:e63.
    >> Share

  321. MOENTADJ R, Wang Y, Bowerman K, Rehaume L, et al
    Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice.
    Ann Rheum Dis. 2021;80:573-581.
    >> Share

  322. KAJIO N, Takeshita M, Suzuki K, Kaneda Y, et al
    Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.
    Ann Rheum Dis. 2021;80:651-659.
    >> Share

    April 2021
  323. ROONGTA R, Chattopadhyay A, Ghosh A
    Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220479.
    >> Share

  324. DERKSEN VFAM, van der Woude D
    Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al.
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220516.
    >> Share

  325. INGEGNOLI F, Cincinelli G, Luppino AF, Favalli EG, et al
    Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2021 Apr 13. pii: annrheumdis-2021-220142.
    >> Share

  326. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Ann Rheum Dis. 2021 Apr 7. pii: annrheumdis-2020-219699.
    >> Share

  327. XIE W, Huang H, Li G, Hao Y, et al
    Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-220112.
    >> Share

  328. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2020-219825.
    >> Share

  329. SO H, Cheng IT, Lau SL, Chow E, et al
    Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-219846.
    >> Share

  330. GUPTA L, Misra DP, Agarwal V, Balan S, et al
    Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al.
    Ann Rheum Dis. 2021;80:e47.
    >> Share

    March 2021
  331. FELTEN R, Devauchelle-Pensec V, Seror R, Duffau P, et al
    Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial.
    Ann Rheum Dis. 2021;80:329-338.
    >> Share

  332. BAER AN, Gottenberg JE, St Clair EW, Sumida T, et al
    Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Ann Rheum Dis. 2021;80:339-348.
    >> Share

  333. AKIYAMA S, Hamdeh S, Micic D, Sakuraba A, et al
    Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
    Ann Rheum Dis. 2021;80:384-391.
    >> Share

  334. LIEW JW, Graef ER
    Rheumatic disease and COVID-19.
    Ann Rheum Dis. 2021;80:e43.
    >> Share

  335. MONTI S, Montecucco C
    Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
    Ann Rheum Dis. 2021;80:e40.
    >> Share

  336. WALLACE B, Washer L, Marder W, Kahlenberg JM, et al
    Patients with lupus with COVID-19: University of Michigan experience.
    Ann Rheum Dis. 2021;80:e35.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016